Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
PMV Pharmaceuticals, Inc. (PMVP) had Consolidated Net Income/Loss of $-17.44M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-17.44M |
|
-- |
|
-- |
|
$21.56M |
|
$-21.56M |
|
$1.93M |
|
$-19.63M |
|
$-19.63M |
|
$-17.44M |
|
$-17.44M |
|
|
Consolidated Net Income/Loss |
$-17.44M |
$-17.44M |
|
$-21.56M |
|
$-22.37M |
|
51.95M |
|
51.95M |
|
$-0.34 |
|
$-0.34 |
|
| Balance Sheet Financials | |
$163.50M |
|
$0.38M |
|
$7.11M |
|
$170.61M |
|
$9.76M |
|
-- |
|
$0.74M |
|
$10.50M |
|
$160.11M |
|
$160.11M |
|
$160.11M |
|
51.95M |
|
| Cash Flow Statement Financials | |
$-18.27M |
|
$28.71M |
|
$0.01M |
|
$40.88M |
|
$51.34M |
|
$10.46M |
|
$1.51M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
16.75 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-18.27M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-10.89% |
|
-10.89% |
|
-10.22% |
|
-10.89% |
|
$3.08 |
|
$-0.35 |
|
$-0.35 |
|